MX2022009167A - Formulaciones para vacuna contra coronavirus. - Google Patents
Formulaciones para vacuna contra coronavirus.Info
- Publication number
- MX2022009167A MX2022009167A MX2022009167A MX2022009167A MX2022009167A MX 2022009167 A MX2022009167 A MX 2022009167A MX 2022009167 A MX2022009167 A MX 2022009167A MX 2022009167 A MX2022009167 A MX 2022009167A MX 2022009167 A MX2022009167 A MX 2022009167A
- Authority
- MX
- Mexico
- Prior art keywords
- nanoparticles
- vaccine formulations
- coronavirus vaccine
- vaccines
- disclosed
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000004176 Alphacoronavirus Species 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966271P | 2020-01-27 | 2020-01-27 | |
| US202062976858P | 2020-02-14 | 2020-02-14 | |
| US202062983180P | 2020-02-28 | 2020-02-28 | |
| US202063048945P | 2020-07-07 | 2020-07-07 | |
| US202063051706P | 2020-07-14 | 2020-07-14 | |
| US202063054182P | 2020-07-20 | 2020-07-20 | |
| US16/997,001 US10953089B1 (en) | 2020-01-27 | 2020-08-19 | Coronavirus vaccine formulations |
| US202063129392P | 2020-12-22 | 2020-12-22 | |
| PCT/US2021/015220 WO2021154812A1 (en) | 2020-01-27 | 2021-01-27 | Coronavirus vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009167A true MX2022009167A (es) | 2022-08-17 |
Family
ID=77079351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009167A MX2022009167A (es) | 2020-01-27 | 2021-01-27 | Formulaciones para vacuna contra coronavirus. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230070886A1 (OSRAM) |
| EP (1) | EP4097123A4 (OSRAM) |
| JP (2) | JP7792339B2 (OSRAM) |
| KR (1) | KR20220141302A (OSRAM) |
| CN (1) | CN115720581A (OSRAM) |
| AU (1) | AU2021214064A1 (OSRAM) |
| BR (1) | BR112022014830A2 (OSRAM) |
| CA (1) | CA3165371A1 (OSRAM) |
| GB (1) | GB2610070A (OSRAM) |
| IL (1) | IL295142A (OSRAM) |
| MX (1) | MX2022009167A (OSRAM) |
| TW (1) | TW202142555A (OSRAM) |
| WO (1) | WO2021154812A1 (OSRAM) |
| ZA (1) | ZA202401922B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| CN113521269A (zh) | 2020-04-22 | 2021-10-22 | 生物技术Rna制药有限公司 | 冠状病毒疫苗 |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| BR112023023035A2 (pt) * | 2021-05-05 | 2024-01-23 | Novavax Inc | Composições de coronavírus e influenza e métodos para usá-las |
| CN113773372B (zh) * | 2021-08-15 | 2024-08-02 | 北京科兴中维生物技术有限公司 | 重组蛋白及其制备方法和应用 |
| CN115960252A (zh) * | 2021-08-26 | 2023-04-14 | 江苏瑞科生物技术股份有限公司 | 新型冠状病毒免疫原性物质、其制备方法和应用 |
| CN118900845A (zh) * | 2021-11-24 | 2024-11-05 | 旗舰创业创新六公司 | 冠状病毒免疫原组合物及其用途 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US20250025549A1 (en) * | 2021-11-30 | 2025-01-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| CN114031675B (zh) * | 2022-01-10 | 2022-06-07 | 广州市锐博生物科技有限公司 | 基于SARS-CoV-2的S蛋白的疫苗和组合物 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| TW202500574A (zh) * | 2023-05-12 | 2025-01-01 | 美商伊科薩瓦克斯有限公司 | 冠狀病毒刺突醣蛋白受體結合域及其用途 |
| WO2025072888A2 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1508615A1 (en) * | 2003-08-18 | 2005-02-23 | Amsterdam Institute of Viral Genomics B.V. | Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| EP2478760A1 (en) * | 2005-05-10 | 2012-07-25 | Monsanto Technology LLC | Genes and uses for plant improvement |
| KR101691574B1 (ko) * | 2008-12-09 | 2017-01-02 | 노바백스, 인코포레이티드 | 변형 ｒｓｖ ｆ 단백질 및 이들의 사용 방법 |
| SG10201602434UA (en) * | 2011-09-30 | 2016-05-30 | Novavax Inc | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
| HK1225631A1 (zh) * | 2013-09-19 | 2017-09-15 | Novavax, Inc. | 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法 |
| IL257800B2 (en) * | 2015-09-03 | 2023-11-01 | Novavax Inc | Immune compositions with improved stability and immunogenicity |
| WO2017161151A1 (en) * | 2016-03-16 | 2017-09-21 | Novavax, Inc. | Vaccine compositions containing modified zika virus antigens |
| EP4599847A3 (en) * | 2016-10-25 | 2025-11-12 | Trustees of Dartmouth College | Prefusion coronavirus spike proteins and their use |
| WO2018170347A1 (en) * | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| CN111499692B (zh) * | 2020-06-16 | 2020-12-04 | 国家纳米科学中心 | 靶向新型冠状病毒covid-19的多肽及其应用 |
-
2021
- 2021-01-27 KR KR1020227029337A patent/KR20220141302A/ko active Pending
- 2021-01-27 IL IL295142A patent/IL295142A/en unknown
- 2021-01-27 AU AU2021214064A patent/AU2021214064A1/en active Pending
- 2021-01-27 WO PCT/US2021/015220 patent/WO2021154812A1/en not_active Ceased
- 2021-01-27 TW TW110103013A patent/TW202142555A/zh unknown
- 2021-01-27 EP EP21747453.5A patent/EP4097123A4/en active Pending
- 2021-01-27 US US17/795,337 patent/US20230070886A1/en active Pending
- 2021-01-27 MX MX2022009167A patent/MX2022009167A/es unknown
- 2021-01-27 CA CA3165371A patent/CA3165371A1/en active Pending
- 2021-01-27 GB GB2212336.8A patent/GB2610070A/en not_active Withdrawn
- 2021-01-27 JP JP2022545141A patent/JP7792339B2/ja active Active
- 2021-01-27 BR BR112022014830A patent/BR112022014830A2/pt unknown
- 2021-01-27 CN CN202180021579.8A patent/CN115720581A/zh active Pending
-
2024
- 2024-03-07 ZA ZA2024/01922A patent/ZA202401922B/en unknown
-
2025
- 2025-10-31 JP JP2025184688A patent/JP2026026092A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202401922B (en) | 2025-04-30 |
| WO2021154812A1 (en) | 2021-08-05 |
| CA3165371A1 (en) | 2021-08-05 |
| EP4097123A1 (en) | 2022-12-07 |
| AU2021214064A1 (en) | 2022-08-18 |
| GB2610070A (en) | 2023-02-22 |
| US20230070886A1 (en) | 2023-03-09 |
| JP2023512648A (ja) | 2023-03-28 |
| IL295142A (en) | 2022-09-01 |
| KR20220141302A (ko) | 2022-10-19 |
| GB202212336D0 (en) | 2022-10-12 |
| JP2026026092A (ja) | 2026-02-16 |
| TW202142555A (zh) | 2021-11-16 |
| EP4097123A4 (en) | 2024-02-14 |
| BR112022014830A2 (pt) | 2022-09-27 |
| JP7792339B2 (ja) | 2025-12-25 |
| WO2021154812A8 (en) | 2022-02-24 |
| CN115720581A (zh) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202401922B (en) | Coronavirus vaccine formulations | |
| WO2023102448A3 (en) | Coronavirus vaccine formulations | |
| EP4494650A3 (en) | Vaccine compositions having improved stability and immunogenicity | |
| BR112023019301A2 (pt) | Formulações de vacina de coronavírus | |
| MY126588A (en) | Intranasal influenza virus vaccine | |
| NO20015073D0 (no) | Vaksiner | |
| WO2002028422A3 (en) | Split enveloped virus preparation for intranasal delivery | |
| WO2010019262A3 (en) | Polyvalent vaccine | |
| TW200722101A (en) | Novel composition | |
| WO2007024941A3 (en) | Polyvalent vaccine | |
| IN2014DN08830A (OSRAM) | ||
| WO2008148057A3 (en) | Cationic lipids compositions and methods for enhancing immune responses to vaccines | |
| PH12022553462A1 (en) | Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof | |
| HK1225631A1 (zh) | 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法 | |
| CY1112575T1 (el) | Βελτιωμενα αδρανοποιημενα εμβολια fcv | |
| PH12018500305A1 (en) | Multivalent vlp conjugates | |
| SG158154A1 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
| AU6721801A (en) | The use of plant oil-bodies in vaccine delivery systems | |
| AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
| MX2025012626A (es) | Composiciones de vacuna sars-cov-2 | |
| MX2025009053A (es) | Formulaciones de vacunas contra el vrs f | |
| MY169061A (en) | Modified marek's disease virus, and vaccines made therefrom | |
| AR121151A1 (es) | Formulaciones para vacuna contra coronavirus | |
| AR127816A1 (es) | Formulaciones de vacunas contra el coronavirus | |
| HK1141793A (en) | Cationic lipids compositions and methods for enhancing immune responses to vaccines |